(firstQuint)A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix in Manitoba, Canada.

 This observational, retrospective, propensity-score matched cohort study using the Manitoba Immunization Monitoring System (MIMS) and the hospital, physician, and prescription claims databases of the Manitoba Health (MH) Database System will assess if Arepanrix cent vaccination during the 2009 pandemic was associated with an increased risk of multiple sclerosis (MS) and other demyelinating conditions not ultimately leading to a multiple sclerosis diagnosis in Manitoba, Canada.

 The data will be collected form the following linked databases: - Manitoba Health (MH) administrative databases - Manitoba Immunization Monitoring System (MIMS) - Manitoba Health Population Registry (MHPR) - Drug Program Information Network (DPIN) - Hospital Abstract Database - The Medical Services database.

 A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix in Manitoba, Canada@highlight

The purpose of this database study is to assess if Arepanrix cent vaccination during the 2009 pandemic was associated with an increased risk of multiple sclerosis (MS) in Manitoba, Canada.

